Skip to content

Rigosertib clinical trial

The EB House Austria in Salzburg initiated a clinical trial, testing efficacy and safety of Rigosertib for RDEB patients with squamous cell carcinoma (PI: Univ.Prof. Dr. Johann Bauer, MBA). The work is funded by DEBRA International (lead applicant: Assoc.Prof. Dr. Andrew South). The trial site in Salzburg is the first centre open for patient recruitment; a second site in London will be opened in autumn.

You can find further information on the website

Back to main navigation
This website uses cookies to give you the best possible service. By using this website, you agree to the use of cookies. Detailed information can be found in our privacy policy .